GlassScriptPhysician profile
Ryane P Doty
NPI 1528531985
$2,221.82
in general payments reported to CMS, 2019-2025
17 companies · $848 in 2025
The $848 reported for 2025 was more than what 77% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $139 · 2022: $30.28 · 2023: $360 · 2024: $844 · 2025: $848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,052.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,052.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $405.80 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $386.92 | 2024-2025 | Fanapt |
| Axsome Therapeutics, INC. | $292.65 | 2024-2025 | Auvelity |
| Indivior INC. | $217.23 | 2022-2025 | Sublocade |
| Supernus Pharmaceuticals, INC. | $137.67 | 2024 | Qelbree |
| Astellas Pharma Global Development | $129.60 | 2023 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $125.18 | 2021-2025 | Trintellix |
| Abbvie INC. | $94.87 | 2021-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $88.55 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $69.02 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $67.77 | 2021-2025 | Lybalvi |
| Lundbeck LLC | $53.62 | 2023-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $37.47 | 2021-2025 | |
| Braeburn INC. | $34.30 | 2025 | Brixadi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.29 | 2025 | Caplyta |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $29.81 | 2024 | Invega Sustenna |
| Harmony Biosciences LLC | $17.07 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryane Doty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.